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Aims: The experience of a compromised sense of “self”, termed ego-dissolution,
is a key feature of the psychedelic experience. This study aimed to validate the
Ego-Dissolution Inventory (EDI), a new 8-item self-report scale designed to measure
ego-dissolution. Additionally, we aimed to investigate the specificity of the relationship
between psychedelics and ego-dissolution.
Method: Sixteen items relating to altered ego-consciousness were included in an
internet questionnaire; eight relating to the experience of ego-dissolution (comprising
the EDI), and eight relating to the antithetical experience of increased self-assuredness,
termed ego-inflation. Items were rated using a visual analog scale. Participants
answered the questionnaire for experiences with classical psychedelic drugs, cocaine
and/or alcohol. They also answered the seven questions from the Mystical Experiences
Questionnaire (MEQ) relating to the experience of unity with one’s surroundings.
Results: Six hundred and ninety-one participants completed the questionnaire,
providing data for 1828 drug experiences (1043 psychedelics, 377 cocaine, 408
alcohol). Exploratory factor analysis demonstrated that the eight EDI items loaded
exclusively onto a single common factor, which was orthogonal to a second factor
comprised of the items relating to ego-inflation (rho = −0.110), demonstrating
discriminant validity. The EDI correlated strongly with the MEQ-derived measure of
unitive experience (rho = 0.735), demonstrating convergent validity. EDI internal
consistency was excellent (Cronbach’s alpha 0.93). Three analyses confirmed the
specificity of ego-dissolution for experiences occasioned by psychedelic drugs. Firstly,
EDI score correlated with drug-dose for psychedelic drugs (rho = 0.371), but not for
cocaine (rho = 0.115) or alcohol (rho = −0.055). Secondly, the linear regression line
relating the subjective intensity of the experience to ego-dissolution was significantly
steeper for psychedelics (unstandardized regression coefficient = 0.701) compared
with cocaine (0.135) or alcohol (0.144). Ego-inflation, by contrast, was specifically
associated with cocaine experiences. Finally, a binary Support Vector Machine classifier
identified experiences occasioned by psychedelic drugs vs. cocaine or alcohol with
over 85% accuracy using ratings of ego-dissolution and ego-inflation alone.
Conclusion: Our results demonstrate the psychometric structure, internal
consistency and construct validity of the EDI. Moreover, we demonstrate the
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close relationship between ego-dissolution and the psychedelic experience. The EDI will
facilitate the study of the neuronal correlates of ego-dissolution, which is relevant for
psychedelic-assisted psychotherapy and our understanding of psychosis.
Keywords: ego dissolution, ego disintegration, ego death, psychedelic, self disturbance, ego boundaries, mystical
experience, hallucinogen
INTRODUCTION
Distortions in the subjective experience of one’s ‘‘self’’, or ‘‘ego’’,
are central to the psychedelic experience (James, 1882; Huxley,
1954; Savage, 1955; Klee, 1963; Leary et al., 1964; Grof, 1976,
1980; Harrison, 2010; Carhart-Harris et al., 2014; Lebedev et al.,
2015). Specifically, a reduction in the self-referential awareness
that defines normal waking consciousness has been reported
with all classical psychedelic drugs (5-HT2A receptor agonists),
including psilocybin (Griffiths et al., 2008, 2011), lysergic acid
diethylamide (LSD; Goodman, 2002; Lyvers and Meester, 2012),
and dimethyltryptamine (DMT; Trichter et al., 2009), as well as
with other psychoactive substances such as nitrous oxide (James,
1882) and ketamine (Vollenweider and Kometer, 2010).
The experience of a compromised sense of self occasioned
by psychedelic drugs has been variously called ego-death (Grof,
1980; Harrison, 2010), ego-loss (Leary et al., 1964), ego-
disintegration (Muthukumaraswamy et al., 2013; Lebedev et al.,
2015) and ego-dissolution (Klee, 1963; Studerus et al., 2010;
Carhart-Harris et al., 2014; Lebedev et al., 2015; Tagliazucchi
et al., 2016). This experience has been interpreted from a
psychoanalytic perspective as a disruption of ego-boundaries,
which results in a blurring of the distinction between self-
representation and object-representation, and precludes the
synthesis of self-representations into a coherent whole (Federn,
1952; Savage, 1955; Fischman, 1983).
It is likely that the prior ‘‘psychology’’ of the subject and the
environmental setting in which they take a psychedelic influences
whether an ego-dissolution experience is welcomed and felt
as something positive, or feared and fought against (Eveloff,
1968; Fischman, 1983; Griffiths et al., 2008; Studerus et al.,
2010, 2012). At one extreme, ego-dissolution is closely related to
blissful mystical experiences such as can be occasioned by certain
spiritual or religious practices (Stace, 1960; Hood, 1975;MacLean
et al., 2012); indeed, loss-of-self was identified by William James
as being a cardinal feature of the mystical experience (James,
1985). These experiences are characterized by a feeling of unity
with one’s surroundings, which is explicitly related to disturbed
ego-boundaries and thus ego-dissolution. Moreover, the mystical
experience is likely to be of therapeutic benefit in psychedelic-
assisted psychotherapy (Leary et al., 1964; Grof, 1980; Griffiths
et al., 2008, 2011; Johnson et al., 2008, 2014). At the other
extreme, it has been argued that self-disturbances and disturbed
ego-boundaries are a core phenomenological feature of psychosis
and schizophrenia (Bleuler, 1950; Laing, 1959; Scharfetter, 1981;
Fischman, 1983; Parnas, 2011; Sass et al., 2011; Northoff, 2014;
Nour and Barrera, 2015), although it remains unclear precisely
how the self-disturbances specific to schizophrenia relate to the
experience of ego-dissolution under psychedelics.
Discussions of altered self-experience have been traditionally
confined to philosophy or descriptive psychopathology (Stace,
1960; Jaspers, 1997). In recent years, however, there has been
increased interest in the neurobiological correlates of the
experience of self (Carhart-Harris and Friston, 2010; Qin
and Northoff, 2011; Carhart-Harris et al., 2014). Psychedelic
drugs may provide a fruitful avenue of research into the
neuronal correlates of normal and abnormal self-awareness
or ego-consciousness (Carhart-Harris et al., 2013, 2014;
Muthukumaraswamy et al., 2013; Roseman et al., 2014; Lebedev
et al., 2015; Tagliazucchi et al., 2016). This research programme,
however, is predicated on the existence of a validated self-report
measure of the ego-dissolution experience.
There currently exist several measures that capture feelings
related to alterations in self-experience (Strassman et al., 1994;
Parnas et al., 2005; Studerus et al., 2010; MacLean et al.,
2012). Dittrich’s APZ (Abnormal Mental States) questionnaire,
and its revised versions, OAV and 5D-ASC, have been used
extensively to characterize altered states of consciousness
occasioned by psychedelic drugs (Dittrich, 1998; Studerus et al.,
2010). These questionnaires purport to capture both positive
and negative experiences of depersonalization and derealization
(‘‘oceanic boundlessness’’ and ‘‘dread of ego dissolution’’,
respectively), as well as additional dimensions of ‘‘visionary
restructuralization’’ (in APZ, OAV and 5D-ASC), ‘‘auditory
alterations’’ and ‘‘vigilance reductions’’ (both in 5D-ASC only;
Dittrich, 1998; Hasler et al., 2004; Wittmann et al., 2007;
Studerus et al., 2010, 2011; Schmid et al., 2015). Recent
psychometric evaluation of the OAV questionnaire, however,
reveals a more complex 11-factor structure, including factors
relating to changes in cognition, perception and mood, as
well as to feelings of unity and disembodiment. At present,
however, there are no validated scales that allow an easy,
reliable and direct uni-dimensional measurement of ego-
dissolution. This presents a barrier to this promising line of
research.
The primary aim of the present study was to develop and
validate the ‘‘Ego-Dissolution Inventory’’ (EDI), a new succinct
8-item self-completed questionnaire designed to operationalize
the experience of ego-dissolution so that its construct validity can
be tested and developed. In order to do this in an efficient way
we chose to utilize online data collection via a large anonymous
internet survey. A secondary aimwas to investigate the specificity
of the relationship between the experience of ego-dissolution and
psychedelic drugs, compared with cocaine and alcohol. These
two comparator drugs were chosen because of their widespread
availability and use inWestern societies. Finally, we aimed to test
the hypothesis that experiences occasioned by classical stimulant
drugs, like cocaine, are in some respects antithetical to the
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psychedelic experience, promoting ego-inflation rather than ego-
dissolution.
MATERIALS AND METHODS
Survey Construction
Ego-Dissolution Inventory Item Selection
Sixteen novel statements relating to the experience of
ego-consciousness were included in this study. Eight of these
were designed to capture the central phenomenon of ego-
dissolution (and the associated feeling of increased union
with one’s surroundings, known as dissolved ego-boundaries),
and particularly how it has been characterized in the context
of the psychedelic experience (Leary et al., 1964; Grof, 1980;
Harrison, 2010). As well as referring to the existing literature
on the psychedelic experience, we also sought the opinion of six
scientists working within the field of psychedelic neuroscience
when choosing the final eight ego-dissolution items, and sought
consensus about the chosen items. The other eight items were
designed to reflect the distinct and largely antithetical experience
of unusually elevated self-assuredness and confidence (which we
refer to as ‘‘ego-inflation’’). The items from these two subscales
were included in the final survey in an interleaved manner
with the intention of minimizing question ‘‘order’’ effects, and
the potential tendency for subjects to indiscriminately endorse
any statement about altered consciousness when reflecting on
an experience with a psychoactive substance (particularly if
that substance can have profound and variegated psychological
effects, as is the case with psychedelics). Items were rated using
a visual analog scale format (0–100, with incremental units of
one) with zero defined as ‘‘No, not more than usually’’, and
100 defined as ‘‘Yes, entirely or completely’’, taking inspiration
from a previous questionnaire on altered states of consciousness
developed by Dittrich (1998) as well as other self-constructed
scales used internally by our team (Carhart-Harris et al., 2012,
2015; Muthukumaraswamy et al., 2013). For the exact wording
of the 16 ego-consciousness items included in the survey see
Table 1.
Survey Structure
Each subject was asked to provide information on their age, sex
and educational background. Subjects also provided information
on their lifetime use of psychedelic drugs and cocaine, as well as
their weekly alcohol consumption (all possible answer options for
educational attainment and drug and alcohol use are presented in
Table 2).
After providing these demographic data, subjects were
given the opportunity to answer questions on up to four drug
experiences: (1) their ‘‘most intense’’ psychedelic experience; (2)
a ‘‘typical’’ psychedelic experience; (3) a ‘‘typical’’ cocaine
experience; and (4) a ‘‘typical’’ alcohol experience. For
psychedelic experiences subjects could further specify the
drug taken (options were: LSD, psilocybin, mescaline, DMT
and ayahuasca). For each experience subjects were asked to
provide information on how long ago the experience was
(options were: ‘‘Today’’, ‘‘Last week’’, ‘‘1–4 weeks’’ ago, ‘‘1–6
TABLE 1 | Factor loadings from exploratory factor analysis of item scores
from 1828 drug experiences (extraction method: principal axis factor;
rotation method: promax with Kaiser normalization; loadings taken from
pattern matrix).
Item: Factor 1 Factor 2
Ego-dissolution Ego-inflation
I felt especially assertive 0.014 0.691
I experienced a dissolution
of my “self” or ego
0.883 −0.040
I felt more important or special
than others
−0.034 0.715
I felt at one with
the universe
0.830 0.010
My ego felt inflated −0.154 0.756
I felt a sense of union
with others
0.700 0.167
I felt especially sure-of-myself 0.151 0.824
I experienced a decrease
in my sense of self-importance
0.663 −0.066
I felt especially keen and
competitive
−0.134 0.725
I experienced a disintegration
of my “self” or ego
0.897 −0.070
I felt like my viewpoint was worth more
than other peoples’
−0.075 0.667
I felt far less absorbed by my
own issues and concerns
0.624 0.112
I felt especially self-confident 0.073 0.847
I lost all sense of ego 0.885 −0.043
I felt especially self-assured 0.156 0.822
All notion of self and identity
dissolved away
0.845 −0.042
Items in bold comprise the Ego-Dissolution Inventory (EDI), whilst the remaining
items relate to ego-inflation. All factor loadings >0.2 are in bold.
months’’ ago, ‘‘6–12 months’’ ago, ‘‘1–5 years’’ ago, ‘‘6–10
years’’ ago, and ‘‘Over 10 years’’ ago). They were also asked
how ‘‘intense’’ the experience was (for psychedelic experiences),
or how ‘‘energized/wired’’ or ‘‘inebriated/drunk’’ they felt (for
cocaine and alcohol experiences, respectively) on a visual analog
scale from 0 to 100, with 0 = ‘‘Not at all’’ and 100 = ‘‘The
most intense/energized/inebriated imaginable’’. The rationale
for enquiring about a typical and most intense experience with
psychedelics was to collect a greater range of possible responses
with regards to psychedelics, which was our primary drug class
of interest.
For each experience subjects were also asked to state the
dose of the drug taken. For psychedelic drugs, subjects were
asked to provide a ‘‘rough/ballpark’’ estimate using an LSD-
equivalent dose; available options ranged from ‘‘No more than
half a tab/50 micrograms of LSD’’ to ‘‘More than 3 tabs/300
micrograms of LSD’’, split into 5 non-overlapping groups. This
was done with the aim of providing a standard reference
against which any non-LSD classical psychedelic could be
compared. For cocaine, the dose options available ranged from:
‘‘less than 1/8 gram’’ to ‘‘More than 2 grams’’, split into six
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TABLE 2 | Demographic data for subjects who provided information for at
least one drug experience.
Total 691
Female 238 (34.44%)
Age at time of survey
Median 28
Inter-quartile range 13
Skewness 1.43
Education
Left school before age 16 (no qualifications) 2 (0.29%)
Left school at 16/GCSE (UK) 29 (4.20%)
High school diploma/A-Level (UK) 68 (9.84%)
Some university (or equivalent) 168 (24.31%)
Bachelor’s degree (or equivalent) 229 (33.14%)
Post-graduate degree (or equivalent) 195 (28.22%)
Lifetime illicit drug use Psychedelic Cocaine
Never 107 (15.48%) 236 (34.15%)
Once only 26 (3.76%) 70 (10.13%)
2–5 times 106 (15.34%) 106 (15.34%)
6–10 times 92 (13.31%) 59 (8.54%)
11–15 times 69 (9.99%) 35 (5.07%)
16–25 times 69 (9.99%) 45 (6.51%)
26–50 times 87 (12.59%) 42 (6.08%)
51–100 times 68 (9.84%) 47 (6.80%)
>100 times 67 (9.70%) 51 (7.38%)
Weekly alcohol consumption
No alcohol 191 (27.64%)
1–6 units 213 (30.82%)
7–12 units 123 (17.80%)
13–18 units 58 (8.39%)
19–24 units 38 (5.50%)
25–30 units 19 (2.75%)
31–36 units 17 (2.46%)
37–42 units 8 (1.16%)
43–48 units 7 (1.01%)
49–54 units 6 (0.89%)
55–60 units 4 (0.58%)
>60 units 7 (1.01%)
non-overlapping groups. For alcohol, the dose options ranged
from: ‘‘Less than 3 units’’ to ‘‘Over 24 units’’, split into nine
non-overlapping groups.
For each drug experience, subjects answered the question
‘‘Do you believe that the experience [induced by the relevant
drug] and your contemplation of that experience have led to
a change in your current sense of personal well-being or life
satisfaction?’’ using a 7-point rating scale (+3 = ‘‘increased very
much’’; +2 = ‘‘increased moderately’’; +1 = ‘‘increased slightly’’;
0 = ‘‘no change’’; −1 = ‘‘decreased slightly’’; −2 = ‘‘decreased
moderately’’; and −3 = ‘‘decreased very much’’), taken from the
persisting effects questionnaire as per Barrett et al. (2015).
Subjects then answered the 16 ego-consciousness items
(Table 1) relating to each specific drug experience in question.
For experiences occasioned by psychedelic drugs, subjects
additionally answered seven questions selected from theMystical
Experiences Questionnaire (MEQ; MacLean et al., 2012; Barrett
et al., 2015). The seven questions selected have been shown
to load onto a single common factor denoting ‘‘Mystical’’
experiences (Barrett et al., 2015), and all relate to the so-called
‘‘unitive’’ experience, which is considered to be a fundamental
feature of the mystical experiences (Stace, 1960; Hood, 1975;
James, 1985). The unitive experience is related to the notion
of dissolved ego-boundaries, and it has been hypothesized
(although never formally investigated) that the phenomenology
of the unitive experience overlaps with that of ego-dissolution
(James, 1882; Leary et al., 1964; Grof, 1980; Harrison, 2010).
The inclusion of the relevant MEQ questions in this survey
allowed us to explicitly test this hypothesis, and provided ameans
of measuring the convergent validity of the ego-dissolution
construct.
The specific MEQ questions included, and their relevant
MEQ30 identifiers (Barrett et al., 2015), were as follows:
‘‘Freedom from the limitations of your personal self and feeling
a unity or bond with what was felt to be greater than your
personal self’’ [MEQ30 Q14], ‘‘Experience of oneness in relation
to an ‘inner world’ within’’ [MEQ30 Q20], ‘‘Experience of the
fusion of your personal self into a larger whole’’ [MEQ30
Q26], ‘‘Experience of unity with ultimate reality’’ [MEQ30 Q28],
‘‘Feeling that you experienced eternity or infinity’’ [MEQ30Q05],
‘‘Experience of oneness or unity with objects and/or persons
perceived in your surroundings’’ [MEQ30 Q06] and ‘‘Experience
of the insight that ‘all is One’’’ [MEQ30 Q18]. Each item was
rated on a 6-point scale, where 0 = ‘‘none, not at all’’; 1 = ‘‘so
slight cannot decide’’; 2 = ‘‘slight’’; 3 = ‘‘moderate’’; 4 = ‘‘strong
(equivalent in degree to any previous strong experience or
expectation of this description)’’; and 5 = ‘‘extreme (more than
ever before in my life and stronger than four)’’. This is consistent
with the standard procedure for completion of the MEQ.
Dissemination of the Survey
This study was approved by the local ethics committee. The
survey was implemented and hosted by the online service Survey
Gizmo1, and was estimated to take 38 min to complete. Survey
Gizmo has comprehensive privacy policies and security features
that maintain the anonymity of responses in line with ethics
requirements.
Participants were recruited to take the online survey via web-
link advertisements posted on Facebook groups, Twitter pages,
email newsletters, and online drug forums with a short request
(‘‘please participate in our anonymous online questionnaire
designed to learn more about experiences with classical
psychedelics, cocaine, and alcohol’’). Recruitment targeted
online communities interested in psychoactive substances
and altered states of consciousness (e.g., Psychedelic Society2,
and Multidisciplinary Association for Psychedelic Studies3),
as well as websites visited by more diverse populations,
(e.g., Reddit4, and Mumsnet5). The collection of IP addresses
and geographical locations of participants was disabled and
participants were informed of the anonymity of their responses.
1http://www.surveygizmo.eu/
2http://www.psychedelicsociety.org.uk
3http://www.maps.org
4https://www.reddit.com/
5http://www.mumsnet.com/
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After reading a summary of the inclusion criteria and
instructions, participants provided informed consent by clicking
‘‘next’’ on the first page of the questionnaire.
Inclusion criteria for participants were: (1) at least 18 years
of age; and (2) had had at least one experience with a classical
psychedelic (LSD, psilocybin, DMT, ayahuasca or mescaline),
cocaine, and/or alcohol. Data collection occurred over a 4-week
period.
Statistical Analysis
Factor Analysis and Definition of Ego-Dissolution
Inventory
We defined a completed form as one in which the subject had
answered all 16 ego-consciousness items relating to at least one
drug experience, and also provided information about the dose
of drug taken, the subjective intensity of the experience, and the
effect on well-being.
Scores for the 16 ego-consciousness items for each complete
form were subjected to an exploratory factor analysis using the
iterated principle axis factor method and an oblique (promax)
rotation, which allowed common factors to be correlated
(Budaev, 2010). The appropriate number of factors to be
extracted was determined by parallel analysis of principal
components using 1000 random draws (Horn, 1965; O’Connor,
2000) and Cattell’s scree plot criterion (Cattell, 1966). Based
on the factor loadings (from the pattern matrix), the 16
ego-consciousness items could be easily separated into two
8-item scales reflecting ‘‘ego-dissolution’’ and ‘‘ego-inflation’’
experiences (full details in ‘‘Results’’ Section). The mean item
scores for both the ego-dissolution and ego-inflation scales were
used as a measure of ego-dissolution and ego-inflation for all
subsequent analysis.
Reliability and Construct Validity
Internal consistency of the scales was assessed with Cronbach’s
alpha (Cronbach, 1951). Convergent validity of the ego-
dissolution scale was assessed using the correlation with our
MEQ-derived measure of unitive experience for psychedelic
experiences. Discriminant validity was demonstrated firstly by
the ability of an exploratory factor analysis to separate the eight
ego-dissolution items from the eight ego-inflation items, and
secondly by demonstrating the specificity of ego-dissolution for
the psychedelic experience over alcohol or cocaine experiences
(see ‘‘Relationship of Ego-Dissolution to Psychedelic Drugs and
Persisting Effects’’ Section).
Relationship of Ego-Dissolution to Psychedelic
Drugs and Persisting Effects
The specificity of the relationship between ego-dissolution and
experiences occasioned by classical psychedelics was tested
in three ways. Firstly we investigated the correlation between
reported drug dose and both ego-dissolution and ego-inflation
for each drug class separately (where drug dose was defined as the
central value for the selected dose range for each experience). For
each drug class the null hypothesis that the dose-ego-dissolution
and dose-ego-inflation correlations were equal was tested using
a 2-tailed t-test of the differences between dependent correlation
coefficients (Field, 2013).
Secondly, we investigated the relationship between the
reported subjective intensity of the experience and ego-
dissolution. Correlations between experience intensity and
ego-experiences within a drug class were investigated in an
identical manner to the dose-response relationships. As ratings
of subjective experience intensity are theoretically comparable
across drug classes (unlike drug doses) we were able to test
the hypothesis that the linear relationship between subjective
intensity and ego-dissolution (or ego-inflation) was different
between psychedelic, cocaine and alcohol experiences by testing
whether the slope of the linear regression line relating subjective
intensity (independent variable) to ego-dissolution or ego-
inflation (dependent variables) is significantly different between
drug classes (using MATLAB’s aoctool [Analysis of covariance
(ANCOVA)] function [MATLAB 2015b, Mathworks]).
Finally, a Support Vector Machine (SVM) classifier
(a common supervised machine learning algorithm) was trained
to distinguish between typical experiences with psychedelics,
cocaine and alcohol using only the ego-dissolution and ego-
inflation score for each experience, in three binary one-v-one
classification tasks (psychedelic vs. cocaine, psychedelics
vs. alcohol, cocaine vs. alcohol). Only ‘‘typical’’ psychedelic
experiences were included in this analysis to avoid classification
problems associated with numerically imbalanced classes (He
and Garcia, 2009). The SVM classifier was implemented in
MATLAB 2015b (Mathworks), as part of the Classification
Learner application, with the following settings: 5-fold cross-
validation, linear kernel, standard normalization transformation
applied to data before entering into SVM classifier.
The correlation between ego-dissolution or ego-inflation and
reported changes in personal well-being was compared both
between and within drug classes using Fisher’s r-to-z transform
and 2-tailed t-test, respectively (Field, 2013).
Spearman’s rho was used to quantify all bivariate correlations.
Statistical significance is defined as p < 0.05 (two-tailed).
Multiple statistical comparisons were performed when analyzing
the correlation between ego-dissolution or ego-inflation and
variables of interest (e.g., drug dose, experience intensity, or
change in well-being) separately for the three drug classes. In
these instances, we applied Bonferroni correction for multiple
comparisons (specifically, six simultaneous comparisons) such
that differences are deemed statistically significant for p< 0.008.
95% confidence intervals were calculated using the bias
corrected and accelerated bootstrap method (1000 samples).
All statistical analysis was performed using SPSS Statistics
(IBM, Version 22), and MATLAB (MathWorks, Version 2015b
including Statistics and Machine Learning Toolbox).
RESULTS
Baseline Demographics of Survey
Responders
Six-hundred and ninety-one subjects completed the online
survey. Table 2 summarizes the demographic information
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for these subjects. Each subject answered questions for a
mean of 2.65 drug experiences (SD 1.18), providing data for
1828 complete drug experiences for analysis (1043 were with
psychedelic drugs: 584 relating to the most intense psychedelic
experience and 459 relating to a typical psychedelic experience,
occurring a median of 1–5 years and 6–12months prior to survey
completion, respectively. 377 were with cocaine, occurring a
median of 1–5 years prior to survey completion. 408 were
with alcohol, occurring a median of 1–4 weeks prior to survey
completion).
Ego-Dissolution Inventory: Factor
Structure and Internal Consistency
To investigate the factor structure of the 16 ego-consciousness
items in a hypothesis-free manner, all questions were submitted
to an exploratory factor analysis. The Kaiser–Meyer–Olkin
measure of sampling adequacy was 0.918 and Bartlett’s test of
sphericity was highly significant (χ2(120) = 22441.7, p < 0.001)
confirming that the data were indeed suitable for factor analysis
(Budaev, 2010).
Both parallel analysis for principle components (Horn, 1965;
O’Connor, 2000) and inspection of the scree plot using Cattell’s
criterion (Cattell, 1966) supported a model with two factors
or components (parallel analysis observed and 95% confidence
interval simulated eigenvalues for the 3rd component were 1.04
and 1.12, respectively). The first component explained 36.6% of
the variance in the sample, and the second component explained
29.5% of the variance in the sample. All other components
explained<7% of the variance in the sample.
The data were therefore subjected to an exploratory factor
analysis to extract two common factors. Factor 1 comprised of the
eight items relating to the experience of ‘‘ego-dissolution’’ whilst
Factor 2 comprised of the eight items relating to the experience
of ‘‘ego-inflation’’. Communality values (the proportion of an
item’s variance that can be explained by the extracted common
factors) ranged from 39% to 82%. Every item loaded strongly
and exclusively onto either Factor 1 or Factor 2, demonstrating
a simple and easily interpretable factor structure (Table 1).
Guided by the results of the exploratory factor analysis, two
8-item scales were derived, one reflecting the experience of ‘‘ego-
dissolution’’, and one reflecting the experience of ‘‘ego-inflation’’
(Table 1). Both scales had excellent internal consistency
(Cronbach’s alpha = 0.93 and 0.91, respectively; Cronbach,
1951). The mean item scores for both the ego-dissolution and
ego-inflation scale were almost perfectly correlated with the
factor scores calculated using the regression method from the
exploratory factor analysis output (both rho > 0.99, p < 0.001).
For ease of interpretability and replication, the mean item scores
from the two scales were used as a measure of ego-dissolution
and ego-inflation for all subsequent analysis.
Construct Validity
For experiences with psychedelic drugs, the score for the
MEQ-derived measure of unitive experience correlated strongly
with ego-dissolution (rho = 0.735 [95% CI 0.704, 0.763],
p < 0.001) providing a clear demonstration of convergent
validity. This measure of unitive experience also correlated
positively with ego-inflation (rho = 0.274 [0.219, 0.332],
p < 0.001) but the strength of this correlation was significantly
weaker than that between unitive experience and ego-dissolution
(t(1040) = 17.8, p < 0.001). In the exploratory factor analysis,
Factor 1 (‘‘ego-dissolution’’) and Factor 2 (‘‘ego-inflation’’)
were essentially orthogonal (rho = −0.11), demonstrating
the discriminant validity of ego-dissolution and ego-inflation
subscales.
Specificity of Ego-Dissolution for
Psychedelic Drugs
Dose-Response Relationship
For experiences with psychedelic drugs, there was a significant
positive correlation between reported drug dose and ego-
dissolution (rho = 0.371 [0.317, 0.427], p < 0.001), and only a
weak correlation between reported drug dose and ego-inflation
(rho = 0.063 [0.003, 0.127], p = 0.043), which did not survive
correction for multiple comparisons (Figure 1A). The difference
between these two correlations was significant (t(1040) = 8.55,
p < 0.001). Conversely, for cocaine, there was a significant
and strong positive correlation between reported drug dose
and ego-inflation (rho = 0.385 [0.390, 0.477], p < 0.001) but
only a weak correlation between drug dose and ego-dissolution
(rho = 0.115 [0.012, 0.211], p = 0.026), which also did not
survive correction for multiple comparisons (Figure 1B). Again,
the difference between these two correlations was significant
(t(374) = 4.88, p< 0.001). For alcohol there was no dose-response
relationship with either ego-dissolution (rho = −0.055 [−0.150,
0.048], p = 0.266) or ego-inflation (rho = −0.054 [−0.148,
0.037], p = 0.328), and no difference between these correlations
(t(405) = 0.031, p= 0.488; Figure 1C).
Intensity-Response Relationship
For experiences with psychedelic drugs, the subjective intensity
of the experience was positively correlated with both ego-
dissolution (rho = 0.577 [0.529, 0.621], p < 0.001) and ego-
inflation (rho = 0.099 [0.040, 0.159], p = 0.001), although the
correlation with ego-dissolution was significantly stronger than
that with ego-inflation (t(1040) = 15.1, p < 0.001). The opposite
pattern was observed for cocaine and alcohol experiences
however, where there was a significantly stronger correlation
between the subjective intensity of these drug experiences and
ego-inflation (Cocaine: rho = 0.545 [0.464, 0.625], p < 0.001.
Alcohol: rho = 0.502 [0.410, 0.582], p < 0.001) than ego-
dissolution (Cocaine: rho = 0.279 [0.180, 0.378], p < 0.001.
Alcohol: rho = 0.334 [0.237, 0.421], p < 0.001); (t(374) = 5.33,
p < 0.001, and t(405) = 4.03, p < 0.001, for cocaine and alcohol
respectively).
ANCOVA analysis was used to fit separate regression
lines relating subjective intensity (predictor variable) to ego-
dissolution or ego-inflation (dependent variables), for each drug
class separately. This analysis confirmed that ego-dissolution
experiences were significantly predicted by experience intensity
(F(1,1822) = 528.4, MSE = 165132.7, p < 0.001), drug class
(F(2,1822) = 636.39, MSE = 198863.7, p < 0.001), and
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FIGURE 1 | Relationship between drug dose and scores for ego-dissolution (blue circles, solid line) and ego-inflation (red squares, dashed line) for
experiences occasioned by different drug classes. (A) Psychedelic experiences (n = 1043). (B) Cocaine experiences (n = 377). (C) Alcohol experiences
(n = 408). Lines represent linear regression lines of best fit, with corresponding R2 and p-value. Error bars represent ±1 SEM.
the interaction between subjective intensity and drug class
(F(2,1822) = 116.29, MSE= 36338, p< 0.001). Follow-upmultiple
comparison tests (Tukey’s HSD criterion) demonstrated that
the slope of the regression line relating experience intensity
to ego-dissolution was significantly steeper for psychedelics
(unstandardized regression coefficient = 0.701 [0.640, 0.762]),
than for cocaine (0.135 [0.088, 0.182]) or alcohol (0.144
[0.098, 0.191], both p < 0.001). There was no difference
between the slopes of the regression lines relating experience
intensity to ego-dissolution for alcohol vs. cocaine (p = 0.984;
Figure 2A).
Ego-inflation experiences were also significantly predicted
by subjective intensity (F(1,1822) = 229.16, MSE = 89120.9,
p < 0.001), drug class (F(2,1822) = 278.5, MSE = 108309.5,
p < 0.001) and the interaction between drug class and intensity
(F(2,1822) = 61.16, MSE = 23785.8, p < 0.001). The slope of the
regression line relating experience intensity to ego-inflation, was,
however, significantly shallower for psychedelics (0.096 [0.043,
0.149]) compared with cocaine (0.632 [0.538, 0.726], p < 0.001)
and alcohol (0.439 [0.357, 0.521], p< 0.001), and was steeper for
cocaine than for alcohol experiences (p= 0.003; Figure 2B).
Support Vector Machine Classifier
As a final demonstration of the specificity of the ego-
dissolution experience for psychedelic drugs, we trained a
SVM binary classifier to distinguish between typical psychedelic
(n = 459), cocaine (n = 377) and alcohol (n = 408)
drug experiences using only the ego-dissolution and ego-
inflation scores. This classifier achieved an accuracy of
90.1% when distinguishing between psychedelic vs. cocaine
experiences (receiver-operator characteristic (ROC) area under
the curve (AUC) = 0.958), and 85.2% accuracy when
distinguishing between psychedelic and alcohol experiences
(ROC AUC = 0.927). By contrast, it performed poorly
when distinguishing cocaine from alcohol experiences (63.4%
accuracy, ROC AUC = 0.685). Classification at chance
level is equivalent to 50% accuracy and ROC AUC = 0.5.
Figure 3 illustrates the relationship between ego-dissolution
and ego-inflation for experiences occasioned by different
drugs.
Ego-Dissolution and Well-Being
As a final exploratory analysis, we sought to investigate the
relationship between ego-experiences and the extent to which
the experience in question changed subjects’ current sense of
personal well-being or life satisfaction. For psychedelic drugs,
the median response on the 7-point rating scale (with possible
answers from −3 to +3) was +2 (+2 = ‘‘Increased moderately’’,
interquartile range = 2, skewness = −0.769, median time
elapsed since experience = 1–5 years), which was significantly
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FIGURE 2 | Relationship between experience intensity and ego-consciousness. (A) Linear regression lines of best fit for relationship between reported
subjective intensity and ego-dissolution for experiences occasioned by psychedelic drugs (blue solid line, R2 = 0.328, p < 0.001), cocaine (red coarsely-broken line,
R2 = 0.078, p < 0.001) or alcohol (black finely-broken line, R2 = 0.084, p < 0.001). (B) Linear regression lines of best fit for relationship between reported subjective
intensity and ego-inflation for experiences occasioned by psychedelic drugs (blue solid line, R2 = 0.012, p < 0.001), cocaine (red coarsely-broken line, R2 = 0.318,
p < 0.001) or alcohol (black finely-broken line, R2 = 0.213, p < 0.001).
greater than the median response for cocaine (0 = ‘‘No
change’’, interquartile range = 0, skewness −0.135, median time
elapsed since experience = 1–5 years) or alcohol (0 = ‘‘No
change’’, interquartile range = 0, skewness = −0.220, median
time elapsed since experience = 1–4 weeks; p < 0.001 for
both comparisons, Wilcoxon rank sum test). The difference
between the mean change in well-being between cocaine and
alcohol was not significant (p = 0.260, Wilcoxon rank sum
test).
There was a trend for a positive correlation between ego-
dissolution score and improvement in well-being across all
drug classes, with this effect reaching statistical significance
after correction for multiple comparisons only for experiences
occasioned by psychedelic drugs (psychedelic: rho = 0.392
[0.342, 0.442], p < 0.001, cocaine: rho = 0.103 [−0.006, 0.204],
p = 0.045; alcohol: rho = 0.084 [−0.009, 0.181], p = 0.091).
This correlation was significantly stronger for psychedelic drugs
compared with either cocaine (Z = 5.15, p < 0.001) or alcohol
(Z = 5.63, p < 0.001), but did not differ between cocaine and
alcohol drug experiences (Z = 0.267, p= 0.789).
Ego-inflation was positively correlated with improvement in
well-being for psychedelic drugs (rho = 0.198 [0.135, 0.263],
p < 0.001). There was a trend for a negative correlation between
ego-inflation and well-being for experiences with cocaine
and alcohol however, although these correlations were non-
significant after correction for multiple comparisons (Cocaine:
rho=−0.083 [−0.198, 0.027], p= 0.107. Alcohol: rho=−0.112
[−0.216, −0.014], p = 0.024). Whilst the correlation between
ego-inflation and well-being was significantly different for
psychedelic drugs compared with both cocaine (Z = 4.71,
p < 0.001) and alcohol (Z = 5.53, p < 0.001), it was not
significantly different between cocaine and alcohol (Z = 0.408,
p= 0.683).
For psychedelic experiences, the positive correlation between
ego-dissolution and increase in well-being was stronger than
between ego-inflation and change in well-being (t(1040) = 5.48,
p < 0.001). For both cocaine and alcohol experiences, the
negative correlation between ego-inflation and change in well-
being was stronger than the correlation between ego-dissolution
and change in well-being (Cocaine: t(374) = 3.14, p = 0.001.
Alcohol: t(405) = 4.13, p< 0.001).
DISCUSSION
The results presented in this study demonstrate the internal
consistency, single-factor psychometric structure and construct
validity the EDI, a new 8-item self-report questionnaire designed
to measure the experience of ego-dissolution. Additionally,
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FIGURE 3 | The relationship between ego-dissolution and ego-inflation
for experiences occasioned by classical psychedelics (blue crosses),
cocaine (red circles) and alcohol (green triangles).
our results demonstrate that ego-dissolution positively
correlates with drug dose and experience intensity specifically
for psychedelic drugs, compared with cocaine or alcohol
experiences. This result mirrors the previously demonstrated
positive relationship between psilocybin dose and altered states
of consciousness, including ‘‘oceanic boundlessness’’ and ‘‘dread
of ego dissolution’’ (as measured by the 5D-ASC questionnaire;
Hasler et al., 2004; Wittmann et al., 2007; Studerus et al., 2011)
and the mystical experience (Griffiths et al., 2011). Indeed, we
also found a positive correlation between psychedelic dose and
unitive experience (rho= 0.307, p< 0.001).
The experience of a coherent and well-circumscribed self
is a cardinal feature of adult human waking consciousness
(Carhart-Harris and Friston, 2010; Carhart-Harris et al., 2014).
Conversely, the experience of ego-dissolution is unfamiliar to
most people, and is related to relatively rare altered states
of consciousness, such as the psychedelic experience (Huxley,
1954; Leary et al., 1964; Grof, 1980; Harrison, 2010; Carhart-
Harris et al., 2014; Lebedev et al., 2015) and the mystical
experience (Stace, 1960; James, 1985). Despite the relative rarity
of the ego-dissolution experience, a fuller understanding of its
neurobiological correlates may inform our understanding of the
therapeutic mechanism of action of psychedelic drugs (Grof,
1980; Griffiths et al., 2008, 2011) and human consciousness
more generally (Carhart-Harris et al., 2014). The development
and validation of the EDI is an important contribution to this
research programme.
An understanding of the neurobiological correlates of self-
experience is also of great importance to a number of mental
health conditions, where the sense of self is disrupted or
compromised (Northoff, 2014). A disrupted sense of self has long
been considered to be a core phenomenological feature of acute
psychosis (Federn, 1952; Laing, 1959; Fischman, 1983; Jaspers,
1997; Scharfetter, 1981; Nour and Barrera, 2015). Recently this
idea has been extended by Sass and Parnas (2003), who propose
that the core phenomenological alteration in schizophrenia is
an ‘‘instability of pre-reflective self-awareness’’, which has been
termed an ‘‘ipseity-disorder’’ or ‘‘self-disorder’’ (Sass et al., 2011).
They argue that saturating all subjective experience is a pre-
reflective awareness of self as the unified subject of experience
(Sass and Parnas, 2003). This notion is closely related to the
feeling of inhabiting a living body embedded in the world
(Stanghellini, 2009). As the pre-reflective sense of self is related
to a feeling of immersion in a social world, ipseity disturbance
may also result in the deficits in social cognition seen in patients
(Parnas and Bovet, 1991; Stanghellini, 2001, 2009; Nelson et al.,
2009; Nordgaard and Parnas, 2014; Nour and Barrera, 2015).
Further research is required to clarify the relationship between
the self-disturbances seen in schizophrenia and psychedelic
states, as well as the relationship between other features of the
psychedelic state and psychosis (Corlett et al., 2009).
Our results represent a necessary step in the demonstration
of the construct validity of ego-dissolution. Construct validity
can be decomposed into discriminant and convergent validity.
Discriminant validity of the EDI was demonstrated by the
fact that items relating to ego-dissolution and those relating
to ego-inflation loaded onto two orthogonal factors in the
exploratory factor analysis. Convergent validity of the EDI was
demonstrated by the strong positive correlation between EDI
and our (MEQ-based) measure of the unitive experience. This
suggests that experiences of ego-dissolution, unity and dissolved
ego-boundaries may be conceptually inseparable (Federn, 1952;
Savage, 1955; Fischman, 1983), occurring together during ‘‘peak’’
psychedelic experiences. Consistent with this hypothesis, the
item ‘‘I felt at one with the universe’’ loaded particularly strongly
on the ‘‘ego-dissolution’’ factor (0.830), together with items
explicitly referring to ‘‘dissolution’’ and ‘‘disintegration’’ of self
or ego (0.883 and 0.897, respectively).
Our measure of ego-inflation, in contrast to ego-dissolution,
showed a significant dose-response relationship with cocaine,
but not psychedelics or alcohol. Although all three drug
classes showed a positive correlation between ego-inflation and
experience intensity, this relationship was strongest for cocaine
and weakest for psychedelic drugs. These results suggest that
experiences occasioned by cocaine are in some sense antithetical
to the psychedelic experience; with cocaine seeming to promote
self-centeredness rather than the selflessness associated with
psychedelics.
Consistent with this hypothesis, a binary SVM classifier
was able to identify experiences occasioned by psychedelic
drugs vs. cocaine or alcohol with over 85% accuracy using
the ego-dissolution and ego-inflation scores alone. This
machine-learning approach may be usefully applied in a
number of contexts. For example, it may help to inform
debates over whether hybrid compounds such as 3,4-
methylenedioxymethamphetamine (MDMA) should be
classed as ‘‘ego-dissolving’’ psychedelic-like agents, ‘‘ego-
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inflating’’ stimulant-like agents, both, or neither. Moreover,
used in conjunction with neurobiological measures, such as
neuroimaging, these tools may help us to identify key (defining)
properties of different psychoactive drugs, as well as non-
drug-induced states, in a data-driven manner, and may inform
novel hypotheses concerning the endogenous role of 5-HT2A
receptors. This may help us to address questions regarding
the similarities and differences of different altered states of
consciousness such as dreaming, psychosis and the psychedelic
state (Carhart-Harris, 2007). More generally, our results suggest
that the specific way in which a drug disturbs ego-consciousness
may inform a novel phenomenologically-based classification
system for psychoactive substances.
Subjects in the present study reported that on average their
reported experiences with psychedelic drugs had a positive and
lasting impact on their well-being, which correlated positively
with the degree of ego-dissolution experienced (rho = 0.392).
This is consistent with previous work, which has established
that mystical (or ‘‘peak’’) experiences occasioned by psilocybin
correlate positively with increases in ‘‘openness’’ (MacLean
et al., 2011), well-being (Barrett et al., 2015), and the
meaningfulness/spiritual significance of the experience (Griffiths
et al., 2008). Similarly, one influential model of LSD therapy
states that the experience of ‘‘ego death and . . . loss of boundaries
between the subject and the objective world, with ensuing
feelings of unity’’ is of great therapeutic benefit (Grof, 1980).
Moreover, lifetime psychedelic use has been associated with
reduced odds ratio of psychological distress, suicidality and
certain mental health problems in large population samples
(Krebs and Johansen, 2013; Hendricks et al., 2015; Johansen and
Krebs, 2015).
Regarding the neurobiology of the psychedelic state, previous
work has indicated that psychedelics disrupt the integrity of
the default-mode network (DMN), a normally well-integrated
network of (mostly cortical) brain regions that display high
metabolic demands, ‘‘connector-hub’’ status and appear to be
involved in high-level functions such as the processing of self-
specific information (Qin and Northoff, 2011; Buckner, 2013;
Speth et al., 2016). Psilocybin and DMT-containing ayahuasca
decrease functional connectivity between key DMN hub regions
(Carhart-Harris et al., 2012; Muthukumaraswamy et al., 2013;
Palhano-Fontes et al., 2015). Psilocybin and LSD also disrupt the
functional segregation between usually well-demarcated brain
networks, promoting increased global integration (Carhart-
Harris et al., 2013; Roseman et al., 2014), which correlates
with ego-dissolution (Tagliazucchi et al., 2016). Disrupted
integrity of the DMN and reduced anticorrelation between
DMN and task-positive network activity may facilitate a less
constrained style of cognition and a weakening of the feeling
of a well-circumscribed self. This may be a psychological
consequence of a less constrained (more entropic) style of
brain activity and a ‘‘collapse’’ in the normal hierarchical
organization of cortical circuits, which normally functions to
finesse perception and cognition by minimizing uncertainty
(Hohwy, 2007; Carhart-Harris and Friston, 2010; Friston, 2010;
Carhart-Harris et al., 2014; Roseman et al., 2014; Tagliazucchi
et al., 2014; Nour and Nour, 2015).
These previous experimental findings suggest that the
integrity of the DMN may be important for normal self-
experience (Qin and Northoff, 2011; Carhart-Harris et al.,
2014). Relatively few studies have explicitly investigated the
neural correlates of ego-dissolution experiences occasioned by
psychedelic drugs. Muthukumaraswamy et al. (2013) found that
the experience of ego-disintegration occasioned by psilocybin
correlated with decreased alpha power in the posterior cingulate
cortex, a DMN hub region, using magnetoencephalography
(MEG). Lebedev et al. (2015) by contrast, found that ego-
dissolution correlated with decreased functional connectivity
between the anterior parahippocampal cortex and higher-level
cortical DMN regions as well as decreased (within-network)
integrity of the salience network, and reduced inter-hemispheric
communication.
A recent study found that the degree of ego-dissolution
occasioned by LSD was correlated with global functional
connectivity (‘‘Functional Connectivity Density’’, as measured
by functional magnetic resonance imaging (fMRI)) in bilateral
temporo-parietal junction (angular gyrus) and bilateral insular
cortex (Tagliazucchi et al., 2016). More generally, this study
reported that LSD induced increases in global connectivity
in more widespread high-level association cortices, which
overlap substantially with the default mode network. A separate
analysis of the same fMRI data further revealed that ego-
dissolution showed a strong inverse correlation with DMN
network integrity (measured as within-network resting state
functional connectivity), and functional connectivity between
the parahippocampus and retrosplenial cortex (Carhart-
Harris et al., 2016). Moreover, significant relationships
were found between ego-dissolution and decreased delta
and alpha power (e.g., in posterior cingulate cortex) as
measured by MEG (Carhart-Harris et al., 2016), replicating
previous findings with psilocybin (Muthukumaraswamy et al.,
2013).
One limitation of these studies is that they either used a
single-item measure of ego-dissolution (Muthukumaraswamy
et al., 2013; Carhart-Harris et al., 2016; Tagliazucchi et al.,
2016), or principle component analysis loadings from an (as
yet) unvalidated questionnaire which included items indirectly
related to ego-dissolution (e.g., perceptual abnormalities;
Lebedev et al., 2015). Thus, the validated EDI allows for a
more rigorous study of the neural correlates of ego-dissolution
experienced in a number of altered states of consciousness,
including those associated with psychedelic drugs and spiritual
practice.
The present study has some limitations. Firstly, the
population sampled was fairly homogenous, which limits
the study’s external validity, and thus our ability to extrapolate
to a broader demographic. Specifically, most of our subjects
were male, under the age of 30, and had at least some university
education. Over half the subjects had used classical psychedelic
drugs on over 10 occasions. This also raises the possibility
that our subjects’ responses were biased by their familiarity
with reports about paradigmatic features of the psychedelic
experience, such as ego-dissolution. Moreover, we did not
collect information on the setting in which the psychedelic
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experiences took place, which is known to influence the
quality of the experience (Leary et al., 1964; Grof, 1976;
Fischman, 1983). Another important limitation of our study is
its retrospective design, which introduces potential inaccuracies
in experience recall. We employed an anonymous internet
questionnaire design to facilitate the collection of a large data
sample of subjects from around the world. Although this
approach has its strengths, it is impossible to verify that the
experiences attributed to psychedelics were indeed caused by
these substances. Finally, we asked subjects to estimate the dose
of psychedelic ingested using ‘‘LSD-equivalent’’ doses, so as
to more easily investigate dose-response relationships across
different classical psychedelics. The inaccuracy introduced by
this approach, however, is likely to have weakened, rather than
strengthened, any observed dose-response relationship between
psychedelics and ego-dissolution.
Given these limitations, future studies should include
a more heterogeneous sampling population, perhaps by
intentionally recruiting subjects from different cultural and
religious backgrounds, to explore the influence of these factors
on ego-dissolution. It would also be of interest to investigate the
relationship between responses on the EDI and other validated
scales, for example the 5D-ASC (Studerus et al., 2010). Finally,
experimental studies in which a range of psychedelic drug doses
are administered to subjects in a blinded manner would be able
to assess how subject-specific factors influence the relationship
between dose and subjective effects, whilst controlling for recall
effects and the effect of setting.
In conclusion, the present study offers initial-phase validation
of the EDI, and adds to the growing evidence that ego-dissolution
is a key phenomenological feature of the psychedelic experience,
which may be studied experimentally. The existence of the
EDI will facilitate future research into the neural correlates of
this experience, which is of relevance for psychedelic-assisted
psychotherapy and the phenomenology of certain psychiatric
conditions.
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